

1 KAMALA D. HARRIS
Attorney General of California
2 LAURA J. ZUCKERMAN
Deputy Attorney General
3 State Bar No. 161896
TIMOTHY E. SULLIVAN
4 Deputy Attorney General
State Bar No. 197054
5 1515 Clay Street, 20th Floor
P.O. Box 70550
6 Oakland, CA 94612-0550
Telephone: (510) 622-4038
7 Fax: (510) 622-2270
E-mail: Timothy.Sullivan@doj.ca.gov
8 *Attorneys for People of the State of California*

FILED
San Francisco County Superior Court

JUL 18 2011

CLERK OF THE COURT

BY: M. Vallejo Deputy Clerk

9 SUPERIOR COURT OF THE STATE OF CALIFORNIA
10 CITY AND COUNTY OF SAN FRANCISCO
11

12
13 **PEOPLE OF THE STATE OF**
CALIFORNIA ex rel. KAMALA D.
14 **HARRIS, Attorney General of the State of**
California,

15 Plaintiff,

16 v.

17 **WARNER-LAMBERT CO.;**
SMITHKLINE BEECHAM CORP.;
18 **AMERICAN HOME PRODUCTION**
CORP.; SOURCE NATURAL, INC.;
19 **SCHERING-PLOUGH HEALTH CARE**
PRODUCTS, INC., PHARMAVITE
20 **CORP.; GENERAL NUTRITION CORP.;**
PERRIGO CO.; TWIN LABORATORIES,
21 **INC. and DOES 1-200,**

22 Defendants.
23
24
25
26
27
28

Case No. 984503
CSH

[~~AMENDED PROPOSED~~] ORDER
MODIFYING CONSENT JUDGMENTS

Date: June 30, 2011
Time: 9:30 a.m.
Dept: 301
Judge: Hon. Peter J. Busch
Trial Date: Vacated
Action Filed: February 6, 1997

1 WHEREAS the Attorney General has provided written notice to the Settling Defendants
2 and other persons that are parties to the February 17, 1998 Consent Judgment, the February 26,
3 1998 Consent Judgment, the June 24, 1998 Consent Judgment, and the November 13, 1998
4 Consent Judgment (together, the "Consent Judgments"), that, pursuant to paragraphs 2.7 and 3.7
5 of the Consent Judgments, as applicable, the Attorney General intends to seek modification of the
6 Consent Judgments; and

7 WHEREAS the Attorney General and the Settling Defendants have conferred for a period
8 of at least ninety (90) days concerning such modification; and

9 WHEREAS the Attorney General and the below-listed Settling Defendants agree,
10 pursuant to paragraphs 2.7 and 3.7 of the Consent Judgments, as applicable, that, as it applies to
11 Access Business Group, LLC (as successor-in-interest to Nutrilite, A Division of Amway Corp.);
12 Bayer HealthCare LLC (as successor-in-interest to Bayer Corporation); Country Life, LLC (as
13 successor-in-interest to Consac Industries); General Nutrition Corp.; GlaxoSmithKline Consumer
14 Healthcare, L.P., GlaxoSmithKline Consumer Healthcare LLC, GlaxoSmithKline LLC and
15 GlaxoSmithKline PLC (as successors-in-interest to SmithKline Beecham Consumer Healthcare);
16 McNEIL-PPC, Inc. (as successor-in-interest to certain rights and obligations of Warner-Lambert
17 Co. regarding Rolaid(s) products); Perrigo Company; Pfizer, Inc. (as successor-in-interest to
18 American Home Products Corp. and Wyeth); and Pharmavite LLC, each of the Consent
19 Judgments should be modified to reflect a new "lowest level currently feasible" for lead in
20 Calcium Supplements and Multiple Vitamin/Minerals;

21 It is hereby ORDERED, that, as it applies to the above-named entities, each of the
22 Consent Judgments, as applicable, is MODIFIED as follows:

23
24 I. All references in each Consent Judgment to "Table 2.3" with respect to Calcium
25 Supplements and Multiple Vitamin/Minerals (but not Antacids) now refer instead to the below
26 Table 2.3A:
27
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

TABLE 2.3A

| DATE | NATURALLY OCCURRING AMOUNT OF LEAD PER 1000 MILLIGRAMS OF CALCIUM |
|------------------|-------------------------------------------------------------------|
| July 1, 1997 | 3.5 micrograms |
| April 1, 1999 | 1.0 microgram |
| November 1, 2011 | 0.8 micrograms |

II. All references in each Consent Judgment to "Table 3.3" with respect to Calcium Supplements and Multiple Vitamin/Minerals (but not Antacids) now refer instead to the below Table 3.3A:

TABLE 3.3A

| DATE | INGREDIENT | NATURALLY OCCURRING AMOUNT OF LEAD |
|------------------|---------------------|------------------------------------|
| November 1, 1998 | Ferrous Fumarate | 0.456 micrograms/gram (mcg/g) |
| November 1, 2011 | Ferrous Fumarate | 0.4 mcg/g |
| November 1, 1998 | Zinc Oxide | 10.0 mcg/g |
| November 1, 2011 | Zinc Oxide | 8.0 mcg/g |
| November 1, 1998 | Magnesium Oxide | 0.5 mcg/g |
| November 1, 2011 | Magnesium Oxide | 0.4 mcg/g |
| November 1, 1998 | Magnesium Carbonate | 0.415 mcg/g |
| November 1, 2011 | Magnesium Carbonate | 0.332 mcg/g |
| November 1, 1998 | Magnesium Hydroxide | 0.5 mcg/g |
| November 1, 2011 | Magnesium Hydroxide | 0.4 mcg/g |
| November 1, 1998 | Zinc Gluconate | 1.0 mcg/g |
| November 1, 2011 | Zinc Gluconate | 0.8 mcg/g |
| November 1, 1998 | Potassium Chloride | 1.32 mcg/g |
| November 1, 2011 | Potassium Chloride | 1.1 mcg/g |

1 III. The following paragraph 2.3.1 is added to each Consent Judgment after paragraph 2.3, if
2 the Consent Judgment contains a paragraph 2.3 that contains a Table 2.3:

3 2.3.1. During the time between the entry of the modification to this Consent Judgment
4 and December 31, 2014, a Settling Defendant need not provide a warning that would
5 otherwise be required by paragraph 2.2 for a Calcium Supplement if the Calcium
6 Supplement meets all of the criteria listed below. This provision may be invoked one time
7 only for that Calcium Supplement, for a period covering no more than three months.

8 (a) No warning would have been required for the Calcium Supplement
9 pursuant to section 2.2 if the Settling Defendant were allowed to exclude the
10 amount of lead specified by the Consent Judgment prior to the modification;

11 (b) The calcium in the Calcium Supplement is obtained from a supplier that
12 had previously supplied calcium of the same form, grade, and functionality, with
13 the same specification for lead concentration in the ingredient, to that Settling
14 Defendant for use in that Calcium Supplement;

15 (c) The supplier is unable to provide calcium with the same form, grade, and
16 functionality with lower lead content, and this inability is documented in a writing
17 from the supplier; and

18 (d) The Settling Defendant invokes this exception by sending written notice to
19 the Attorney General prior to shipping the Calcium Supplement and provides
20 evidence showing that criteria (a) through (c), above, have been satisfied.

21
22 IV. The following paragraph 2.7.1 is added to each Consent Judgment after paragraph 2.7, if
23 the Consent Judgment contains a paragraph 2.7:

24 2.7.1 The Attorney General shall not seek to modify the Consent Judgment pursuant to
25 Section 2.7 with respect to the naturally occurring levels set forth in Table 2.3A until three
26 years have elapsed from the date of entry of this modification. This restriction no longer
27 applies, however, if a Settling Defendant seeks to modify the Consent Judgment pursuant
28 to Section 2.8 prior to the expiration of the three-year period.

1 V. The following paragraph 3.7.1 is added to each Consent Judgment after paragraph 3.7, if
2 the Consent Judgment contains a paragraph 3.7:

3 3.7.1. The Attorney General shall not seek to modify the Consent Judgment pursuant to
4 Section 3.7 with respect to the naturally occurring levels set forth in Table 3.3A until three
5 years have elapsed from the date of entry of this modification. This restriction no longer
6 applies, however, if a Settling Defendant seeks to modify the Consent Judgment pursuant
7 to Section 3.8 prior to the expiration of the three-year period.

8
9 In addition, it is hereby ORDERED that

10
11 VI. Pfizer Inc. is bound by and shall have the benefit of the terms of the November 13, 1998
12 Consent Judgment as modified by this Order. Exhibit B of the November 13, 1998
13 Consent Judgment is hereby amended to include Pfizer Inc.'s Calcium Supplement
14 products and Multi-Vitamin/Minerals products identified in Exhibit 1 hereto.

15
16 VII. Bayer HealthCare LLC is bound by and shall have the benefit of the terms of the
17 November 13, 1998 Consent Judgment as modified by this Order. Exhibit B of the
18 November 13, 1998 Consent Judgment is hereby amended to include Bayer HealthCare
19 LLC's Calcium Supplement products and Multi-Vitamin/Minerals products identified in
20 Exhibit 2 hereto.


21
22 VIII. GlaxoSmithKline Consumer Healthcare, L.P., GlaxoSmithKline Consumer Healthcare
23 LLC, GlaxoSmithKline LLC and GlaxoSmithKline PLC ("GSK") are bound by and shall
24 have the benefits of the terms of the November 13, 1998 Consent Judgment as modified
25 by this Order. Exhibit B of the November 13, 1998 Consent Judgment is hereby amended
26 to include GSK's Calcium Products identified in Exhibit 3 hereto.

1 IX. McNEIL-PPC, Inc. is bound by and shall have the benefits of the terms of the November
2 13, 1998 Consent Judgment as modified by this Order. Exhibit B of the November 13,
3 1998 Consent Judgment is hereby amended to include Roloids(r) as Antacid products of
4 McNEIL-PPC, Inc.
5

6 In all other respects the Consent Judgments are to remain unchanged.
7

8 Dated:

9 JUL 15 2011

10 
11 Judge of the Superior Court
12 **PETER J. BUSCH**

13 OK2009901140
14 90197024_3.docx
15
16
17
18
19
20
21
22
23
24
25
26
27
28